Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis


ABSTRACT

BACKGROUND
Idiopathic pulmonary fibrosis is progressive and often fatal; causes of familial clustering of the disease are unknown. Germ-line mutations in the genes hTERT and hTR, encoding telomerase reverse transcriptase and telomerase RNA, respectively, cause autosomal dominant dyskeratosis congenita, a rare hereditary disorder associated with premature death from aplastic anemia and pulmonary fibrosis.

METHODS
To test the hypothesis that familial idiopathic pulmonary fibrosis may be caused by short telomeres, we screened 73 probands from the Vanderbilt Familial Pulmonary Fibrosis Registry for mutations in hTERT and hTR.

RESULTS
Six probands (8%) had heterozygous mutations in hTERT or hTR; mutant telomerase resulted in short telomeres. Asymptomatic subjects with mutant telomerase also had short telomeres, suggesting that they may be at risk for the disease. We did not identify any of the classic features of dyskeratosis congenita in five of the six families.

CONCLUSIONS
Mutations in the genes encoding telomerase components can appear as familial idiopathic pulmonary fibrosis. Our findings support the idea that pathways leading to telomere shortening are involved in the pathogenesis of this disease.
Dyskeratosis congenita is a rare hereditary disorder initially described on the basis of a triad of mucocutaneous manifestations: skin hyperpigmentation, oral leukoplakia, and nail dystrophy. The most common cause of death in patients with dyskeratosis congenita is bone marrow failure due to aplastic anemia. Pulmonary disease is present in 20% of patients and is the second most common cause of death. The X-linked form of dyskeratosis congenita is severe and associated with mutations in the DKC1 gene. Autosomal dominant cases of dyskeratosis congenita are rare, can present later in adulthood, and often lack the classic skin manifestations. In some families, the hematopoietic defects develop first, implying that despite the originally given name, dyskeratosis is not canonical. Heterozygous mutations in hTERT and hTR, the essential components of telomerase, underlie the genetic defect in families with dominant inheritance, indicating that half the usual dose of telomerase is inadequate for telomere maintenance, and tissues of high turnover, such as the bone marrow, are susceptible.

In autosomal dominant dyskeratosis congenita, anticipation can be seen in which phenotypes present earlier and more severely in successive generations. This pattern implies that in these patients, it is not the telomerase mutation itself but the short telomeres that determine the severity of the disease.

We recently identified a pedigree with autosomal dominant dyskeratosis congenita that carried a null hTERT allele but lacked the typical mucocutaneous features. In this kindred, pulmonary fibrosis was dominantly transmitted and was the only manifestation of disease in one mutation carrier. The clinical presentation and pattern of fibrosis in this subject were typical of the idiopathic form of the disease. Since familial idiopathic pulmonary fibrosis is also dominantly inherited, we hypothesized that telomere shortening causes this disease and that mutations in telomerase may contribute to it.

METHODOLOGY

METHODS

SUBJECTS

Subjects and their families were recruited into the Vanderbilt Familial Pulmonary Fibrosis Registry on the basis of the presence of two or more cases of idiopathic pulmonary fibrosis. (We did not limit families to those in which only first-degree relatives were affected.) Subjects were excluded from the study if they had a secondary cause of pulmonary fibrosis or if they had skin manifestations suggestive of dyskeratosis congenita. Subjects were recruited from the Vanderbilt Idiopathic Pulmonary Fibrosis Clinic or were referred from other sites in North America between 1996 and 2004. The study was approved by the local institutional review boards, and written informed consent was obtained from all subjects. Diagnostic confirmation was based on a detailed clinical assessment (Table 1, and Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). We used the consensus classification of idiopathic interstitial pneumonia in individual cases. At the time the
registry was accessed, all 73 probands were reported by their clinicians to be North Americans of European descent.

**SEQUENCE ANALYSIS**
Genomic DNA was isolated from peripheral blood with the use of standard methods. We amplified and sequenced hTR in both directions, as described previously.21 We amplified and sequenced the 16 exons of hTERT and its 3’ untranslated region with the use of primers listed in Table 2 of the Supplementary Appendix. Amplicons of hTERT were sequenced in one direction, and suspected changes were confirmed in the opposite strand. Mutations in the probands and their relatives were confirmed by bidirectional sequencing. Sequences were inspected manually with the use of Sequencher software, and variants were compared with public databases. Coding and noncoding variants are listed in Table 3 of the Supplementary Appendix.

**TELOMERES AND TELOMERASE**
A reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay was performed with the use of RNA isolated from peripheral blood to make complementary DNA (cDNA). Primers were designed to span exons where a mutation was predicted to alter splicing; primer sequences are available on request. PCR products were cloned, and the sequence was verified.

The average length of telomeres was measured in peripheral-blood lymphocytes by flow fluorescence in situ hybridization (FISH), as described previously.28 Point mutations were generated, and the telomerase complex was reconstituted in vitro.24 Telomerase activity was assayed without amplification, with the use of a modified direct assay.29,30

---

**RESULTS**

**MUTATIONS AFFECTING TELOMERASE COMPONENTS**
Of 73 probands who were screened, 6 (8%) had heterozygous mutations in hTERT or hTR. Five probands had mutations in hTERT (two missense, two splice junction, and one frameshift), and one proband had a mutation in hTR (Table 1, and Fig. 1 of the Supplementary Appendix). None of the hTERT mutations were present in 623 unaffected subjects, as determined in other studies.23,31 Of these subjects, 140 described themselves as white, with the rest describing themselves as black.

<table>
<thead>
<tr>
<th>Proband No.</th>
<th>Mutation</th>
<th>Age At Onset of Study</th>
<th>Presenting Symptom</th>
<th>Smoking History</th>
<th>Pulmonary Function</th>
<th>Findings on Lung Biopsy</th>
<th>Complete Blood Count</th>
<th>Telomere Mutations in Idiopathic Pulmonary Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>AII.1</td>
<td>hTERT</td>
<td>77</td>
<td>Dyspnea</td>
<td>None</td>
<td>TLC 4.45 (68)</td>
<td>FVC 3.02 (68)</td>
<td>WBC 14.2 (76)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>BIII.5</td>
<td>hTERT</td>
<td>58</td>
<td>Cough</td>
<td>None</td>
<td>TLC 3.17 (44)</td>
<td>FVC 2.10 (44)</td>
<td>WBC 12.5 (49)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>CII.7</td>
<td>hTERT</td>
<td>58</td>
<td>Dyspnea</td>
<td>30 pack-years</td>
<td>TLC 5.28 (69)</td>
<td>FVC 3.55 (69)</td>
<td>WBC 12.8 (47)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>DIII.2</td>
<td>hTERT</td>
<td>48</td>
<td>Dyspnea</td>
<td>32 pack-years</td>
<td>TLC 3.28 (68)</td>
<td>FVC 1.31 (43)</td>
<td>WBC 13.1 (43)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>EII.2</td>
<td>hTERT</td>
<td>68</td>
<td>Dyspnea</td>
<td>None</td>
<td>TLC 3.25 (68)</td>
<td>FVC 1.69 (47)</td>
<td>WBC 12.5 (54)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
<tr>
<td>FIII.5</td>
<td>hTR</td>
<td>60</td>
<td>Dyspnea</td>
<td>None</td>
<td>TLC 2.48 (51)</td>
<td>FVC 1.2 (45)</td>
<td>WBC 7.07 (32)</td>
<td>Telomere Mutations in Idiopathic Pulmonary Fibrosis</td>
</tr>
</tbody>
</table>

*Identifiers for all probands refer to subjects shown in Figure 1. TLC denotes total lung capacity, FVC forced vital capacity, DLCO carbon monoxide diffusing capacity, WBC white cells, Hgb hemoglobin, IVS intervening sequence between exons (intronic), and NA not available.

---

Copyright © 2007 Massachusetts Medical Society. All rights reserved.
Figure 1. Pedigrees of Six Probands with Telomerase Mutations.

Arrows point to the proband in each family, and bold italic numbers indicate subjects for whom DNA was available for sequencing. Subjects in whom telomere length was measured are indicated by asterisks. Mutation status is indicated by the symbols shown in the key, with squares indicating male sex and circles indicating female sex. Deceased family members are indicated by slashes through the symbols. In Family D, Subject DII.1 is an obligate carrier, given that two of his children carry the mutation and the mother does not. A total of 19 subjects with confirmed idiopathic pulmonary fibrosis are included among the six families shown. The seven asymptomatic carriers in younger generations were on average 11 years younger than the probands at the time of diagnosis: 40, 44, 46, 50, 52, 55, and 68 years of age. In Family F, three subjects had aplastic anemia, and Subject FIII.16 died from acute myeloid leukemia, probably in the setting of aplastic anemia. IPF denotes idiopathic pulmonary fibrosis.
Hispanic, or Asian. The hTR mutation was also absent in 194 healthy controls. Of these subjects, 123 described themselves as white, with the remaining subjects describing themselves as black, Hispanic, or Asian.  

**Mutations Associated with Disease and Short Telomeres**

To determine whether telomerase mutations segregated with idiopathic pulmonary fibrosis in families, we examined the pedigrees. The pattern of inheritance was consistent with autosomal dominant inheritance of the disease (Fig. 1). The mutant allele was present in affected subjects and was generally absent in asymptomatic subjects of the same generation. We identified mutation carriers who did not have symptoms of the disease. These subjects were on average 11 years younger than the probands at the time of diagnosis (Fig. 1). This observation is consistent with the variable penetrance associated with familial idiopathic pulmonary fibrosis and also suggests that the onset of disease may be age dependent.

To assess whether mutant telomerase is associated with short telomeres, we measured the telomere length in lymphocytes. The average telomere length was significantly less in the probands and asymptomatic mutation carriers than in their relatives who did not carry the mutation ($P=0.006$) (Fig. 2A). A comparison of the telomere length in mutation carriers with that in 400 healthy controls, according to age, showed that mutation carriers fell below the 10th percentile of the controls ($P=0.018$), whereas their relatives who were noncarriers clustered near the median ($P=0.575$) (Fig. 2B). Mutant telomerase was therefore associated with short telomeres.

**Impaired Activity of Mutant Telomerase**

We next examined the consequences of hTERT and hTR mutations on telomerase function. We first examined the two missense mutations in hTERT, glutamine replacing leucine at residue 55 (Leu55Gln) and methionine replacing threonine at residue 1110 (Thr1110Met). The Leu55Gln substitution identified in the proband of Family A is in a highly conserved region of the N-terminal; an amino acid substitution of Leu55 may alter telo-
merase RNA binding and thus the catalytic efficiency of telomerase. The Thr1110 residue is also highly conserved and lies in the C-terminal domain of hTERT, a domain that is thought to mediate recruitment of telomerase to the telomere. Both mutant versions of hTERT (Leu55Gln and Thr1110Met) had impaired activity, as compared with the wild-type enzyme (Fig. 3C and 3D). Since heterozygous mutations sometimes interfere with the function of the wild-type allele, we assayed the telomerase activity of a mixture of wild-type and mutant versions of the enzyme and observed no dominant negative effect (data not shown).

We also examined the effect of the hTR 98 G→A substitution (observed in the proband of Family F) on telomerase activity. This mutation is predicted to impair base pairing in a helix in the essential pseudoknot domain of hTR. Moreover, since 98G is conserved in telomerase RNA in all vertebrates, a mutation at this site is expected to alter activity. When telomerase was reconstituted with the mutant hTR 98A allele, activity was severely impaired (Fig. 3C and 3D).

We next examined the potential consequences of the three mutations in hTERT. The deletion of nucleotide C at codon 112 in the proband of Family C leads to a frameshift mutation and is predicted to result in a nonfunctional, truncated protein. Both splice-junction mutations in Family B and Family D occur at consensus sequences that are conserved in 99.9% of all eukaryotic genes and are therefore predicted to alter splicing. We examined the cDNA of primary cells from a subject in Family D who carried the IVS9-2 A→C mutation, indicating that the heterozygous mutation at this consensus splice junction leads to the skipping of exon 10 but retention of the reading frame (Fig. 3E). According to these findings, obtained by RT-PCR, synthesis of a protein of nearly full length is predicted. However, this mutant TERT is predicted to lack an essential motif (the C motif) in the reverse-transcriptase domain and thus to result in a functionally null protein (Fig. 3A).

Clinical Review

We reexamined the probands for the most common features of dyskeratosis congenita. None of the probands had cytopenias (Table 1), and none had any of the classic features of dyskeratosis congenita at the time of diagnosis. To discern whether these six families had hidden cases of dyskeratosis congenita, we queried family members and medical records for evidence of aplastic anemia. We identified no cases of aplastic anemia in five of the six families. In Family F, we identified three subjects with aplastic anemia and a fourth subject with probable aplastic anemia (Fig. 1). In this family, subjects with a hematopoietic defect died at a younger age (25, 26, 31, and 81 years, with a mean of 41 years) than did those with idiopathic pulmonary fibrosis (76, 70, 63, 57, 60, and 66 years, with a mean of 65 years). We also explored the possibility that asymptomatic mutation carriers with short telomeres had cytopenias that reflected early changes of aplastic anemia. We examined complete blood counts in members of five of the families — Family A, Family B, Family C, Family D, and Family E — and found no abnormalities.

To assess whether the pulmonary fibrosis in the probands could be differentiated from other cases of idiopathic pulmonary fibrosis, we reviewed the clinical data. The presentation, age at onset, and findings on computed tomography were indistinguishable from those of other cases of the disease (Table 1 and Fig. 4). None of these subjects had a response to trials of immunosuppressive therapy. In all cases, the proband had
undergone lung biopsy, and five of the six probands had the common lesion of usual interstitial pneumonia. A biopsy specimen obtained from the sixth proband showed idiopathic interstitial pneumonia, not classifiable. Different idiopathic interstitial pneumonia pathological lesions have been described in the same patient, as well as in members of the same family with the disease, underscoring the need for precise molecular characterization.\textsuperscript{4,35}
Figure 4. High-Resolution Computed Tomographic Images of the Midlung (Panel A through Panel D) and Bases (Panel E through Panel H) in Probands in Four Families.

Subject numbers are shown in the upper right-hand corners of the panels. In all four probands, subpleural honeycombing and increased reticular densities are visible in the views at the bases. These changes extend up to the midlung and apices in some subjects with more advanced stages of disease (e.g., Subject DIII.2).

DISCUSSION

We have shown that mutant telomerase is associated with familial idiopathic pulmonary fibrosis, which suggests that the spectrum of disease caused by telomere shortening is more extensive than previously appreciated and that a subgroup of families with pulmonary fibrosis falls on that spectrum.

Short dysfunctional telomeres activate a DNA damage response that leads to cell death or cell-cycle arrest. This response is manifested clinically as organ failure in tissues of high turnover (bone marrow, skin, and gastrointestinal tract) in patients with, and in an animal model of, dyskeratosis congenita. The presence of pulmonary fibrosis in dyskeratosis congenita, along with the presence of telomerase mutations in some families with idiopathic pulmonary fibrosis, suggests that bronchoalveolar epithelium is also constantly replaced and relies on local progenitor reserves that are limited by short telomeres.

On the basis of these findings, we propose that the fibrotic lesion in patients with short telomeres is provoked by a loss of alveolar cells rather than by a primary fibrogenic process, such as one that would seem to occur in autoimmune disease associated with lung fibrosis. This view is supported by the fact that misfolded surfactant protein C (present in affected subjects carrying a mutation in the corresponding gene) appears to be toxic to alveolar cells. Therefore, it is possible that in some types of fibrosis, damage of epithelial cells leads to a remodeling response that appears clinically as usual interstitial pneumonia. Taken together, these considerations may explain the lack of success in reversing idiopathic fibrosis with agents that modulate immune or inflammatory signals and support the idea that at least in some cases, strategies aimed at preventing the loss of alveolar cells, or local responses to such cell loss, may have a greater clinical impact.

Although mutations in the essential components of telomerase do not seem to account for a majority of cases of familial pulmonary fibrosis, telomere shortening as a process may still contribute to the pathogenesis. There is evidence that short telomeres, rather than telomerase mutations, correlate with disease in dyskeratosis congenita. In an animal model of dyskeratosis congenita, wild-type mice who inherit short telomeres appear to have an occult genetic disease and display phenotypes similar to those in mice that are heterozygous for mutant telomerase RNA. Acquired states that increase tissue turnover are also associated with short telomeres. One study showed that both current and former smokers had shorter telomeres than did age-matched nonsmokers. In addition, there is some evidence that telomeres of the alveolar epithelium in smokers are shorter than those of the alveolar
epithelium in nonsmokers. It is therefore possible that somatic telomere shortening, caused by conditions that increase cell turnover (e.g., smoking), could contribute to fibrosis. In a study evaluating disease onset in relatives of familial probands with idiopathic pulmonary fibrosis, cigarette smoking and older age were the strongest predictors. Because telomere shortening occurs with aging and can be acquired, it may contribute to the disease pathogenesis even in persons with wild-type telomerase.

Our study will have clinical implications, assuming that our findings are replicated by other investigators. As suggested by the experience in aplastic anemia, patients who carry either hTERT or hTR mutations are unlikely to have a response to immunosuppression and may be good candidates for investigational clinical trials. The presence of a diagnostic genetic test gives patients at risk and their clinicians a chance to consider early screening and evaluation tailored to identification of complications of dyskeratosis congenita. Patients with dyskeratosis congenita, especially those with severe forms, have a predisposition to cancers of the skin, hematopoietic system, and oral mucosa.

Finally, telomere length may serve as a surrogate marker for the identification of patients at greatest risk for carrying mutant telomerase genes.

In our series of 15 subjects, longer telomeres appeared to predict the absence of a telomerase mutation, although this finding requires verification in larger studies. Since the consequences of carrying mutant telomerase genes can appear in adulthood as either idiopathic pulmonary fibrosis or aplastic anemia without dyskeratosis, the consideration of such cases as part of a syndrome of telomere shortening may heighten the index of suspicion and facilitate diagnosis.

Supported by a grant (NCI K08 118416) from the National Institutes of Health (NIH) (to Dr. Armanios), the Richard C. Ross Johns Hopkins School of Medicine Clinician Scientist Award (to Dr. Armanios), the Maryland Cigarette Restitution Fund (to Johns Hopkins University), a grant from the Johns Hopkins Institute for Cellular Engineering Pilot Program (to Dr. Greider), a grant (HL K08 85406) from the NIH and the Francis Family Foundation (to Dr. Lawson), a grant (AI029524) from the NIH and grants (MOP38075 and GM170942) from the Canadian Institute of Health Research (to Dr. Lansdorp), a Vanderbilt Discovery Grant and the Rudy W. Jacobson endowment (to Dr. Loyd), and a grant (M01 RR-00095) from the National Center for Research Resources of the NIH to support the Vanderbilt Clinical Research Center.

Dr. Lansdorp reports being a founding shareholder in Repeat Diagnostics, a company that specializes in length measurement of leukocyte telomeres with the use of flow FISH. No other potential conflict of interest relevant to this article was reported.

We thank the subjects and their families who participated in this study and their clinicians, especially Drs. Adaani Frost and Keith E. Kelly and nurses Wendi Mason and Rhonda Greer; the Johns Hopkins Fragment Analysis Laboratory and Laura Kasch-Semenza for their help with DNA sequencing; Melissa Prince for technical assistance; and Dr. David Valle for his valuable advice.

REFERENCES


Downloaded from www.nejm.org at WELCH MEDICAL LIBRARY-JHU on November 5, 2009. Copyright © 2007 Massachusetts Medical Society. All rights reserved.
et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003;362:1628-30.

Copyright © 2007 Massachusetts Medical Society.